Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

Acta Neuropathologica

Volumn 124, Issue 3, 2012, Pages 411-424

  Brück, Wolfgang ^a   Pförtner, Ramona ^a   Pham, Trinh ^b   Zhang, Jingya ^b   Hayardeny, Liat ^c   Piryatinsky, Victor ^c   Hanisch, Uwe Karsten ^a   Regen, Tommy ^a   Van Rossum, Denise ^d   Brakelmann, Lars ^e   Hagemeier, Karin ^e   Kuhlmann, Tanja ^e   Stadelmann, Christine ^a   John, Gareth R ^b   Kramann, Nadine ^a   Wegner, Christiane ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Pharmacology Unit   (Israel)

^d SARTORIUS STEDIM BIOTECH GMBH   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Astrocytes; Cuprizone; Demyelination; Laquinimod; Multiple sclerosis; NF B

Indexed keywords

CUPRIZONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAQUINIMOD; MYELIN; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; AXONAL INJURY; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROTECTION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GLIA CELL; GLIOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVE CELL; NERVE FIBER; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; WILD TYPE;

ANIMALS; ASTROCYTES; AXONS; CUPRIZONE; DEMYELINATING DISEASES; MALE; MICE; MYELIN SHEATH; NF-KAPPA B; OLIGODENDROGLIA; QUINOLONES;

EID: 84865863065     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-012-1009-1     Document Type: Article

References (49)

1. Acarin L, Gonzalez B, Castellano B (2001) Triflusal posttreatment inhibits glial nuclear factor-kappaB, downregulates the glial response, and is neuroprotective in an excitotoxic injury model in postnatal brain. Stroke 32:2394-2402 (Pubitemid 32954814)
2. Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271-278 (Pubitemid 32510589)
3. Blakemore WF (1972) Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J Neurocytol 1:413-426
4. Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, Karmally S, Green EJ, Bethea JR (2005) Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med 202: 145-156 (Pubitemid 41002917)
5. Brambilla R, Persaud T, Hu X, Karmally S, Shestopalov VI, Dvoriantchikova G, Ivanov D, Nathanson L, Barnum SR, Bethea JR (2009) Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J Immunol 182:2628-2640
6. Brex PA, Jenkins R, Fox NC, Crum WR, O'Riordan JI, Plant GT, Miller DH (2000) Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54:1689-1691 (Pubitemid 30226819)
7. Bruck W, Zamvil SS (2012) Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Clin Pharmacol 5:245-256
8. Bruck W, Wegner C (2011) Insight into the mechanism of laquinimod action. J Neurol Sci 306:173-179
9. Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, Astrom M, Hedlund G (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 130:163-172 (Pubitemid 35240003)
10. Carter SL, Muller M, Manders PM, Campbell IL (2007) Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFNgamma but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro. Glia 55:1728-1739 (Pubitemid 47612859)
11. Chard DT, Griffin CM, Parker GJM, Kapoor R, Thompson AJ, Miller DH (2002) Brain atrophy in clinically early relapsingremitting multiple sclerosis. Brain 125:327-337 (Pubitemid 34127435)
12. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371:2085-2092 (Pubitemid 351842581)
13. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366:1000-1009
14. Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR, O'Riordan JI, Plant GT, Thompson AJ, Miller DH (2002) Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:141-147
15. de Freitas MS, Spohr TC, Benedito AB, Caetano MS, Margulis B, Lopes UG, Moura-Neto V (2002) Neurite outgrowth is impaired on HSP70-positive astrocytes through a mechanism that requires NF-kappaB activation. Brain Res 958:359-370 (Pubitemid 35441189)
16. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, Van der Valk P (1997) Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 56:10-20 (Pubitemid 127470323)
17. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399 (Pubitemid 27153632)
18. Hiremath MM, Saito Y, Knapp GW, Ting JP, Suzuki K, Matsushima GK (1998) Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 92:38-49 (Pubitemid 29015988)
19. Kim HJ, Miron VE, Dukala D, Proia RL, Ludwin SK, Traka M, Antel JP, Soliven B (2011) Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J 25:1509-1518
20. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202-2212
21. Lee SC, Dickson DW, Liu W, Brosnan CF (1993) Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J Neuroimmunol 46:19-24 (Pubitemid 23284245)
22. Li L, Lundkvist A, Andersson D, Wilhelmsson U, Nagai N, Pardo AC, Nodin C, Stahlberg A, Aprico K, Larsson K, Yabe T, Moons L, Fotheringham A, Davies I, Carmeliet P, Schwartz JP, Pekna M, Kubista M, Blomstrand F, Maragakis N, Nilsson M, Pekny M (2008) Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab 28:468-481 (Pubitemid 351304260)
23. Liu J, Zhao ML, Brosnan CF, Lee SC (1996) Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist. J Immunol 157:3569-3576 (Pubitemid 126449171)
24. Mason JL, Toews A, Hostettler JD, Morell P, Suzuki K, Goldman JE, Matsushima GK (2004) Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions. Am J Pathol 164:1673-1682 (Pubitemid 38529770)
25. Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107-116
26. Miron VE, Zehntner SP, Kuhlmann T, Ludwin SK, Owens T, Kennedy TE, Bedell BJ, Antel JP (2009) Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 174:1880-1890
27. Moharregh-Khiabani D, Blank A, Skripuletz T, Miller E, Kotsiari A, Gudi V, Stangel M (2010) Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS One 5:e11769
28. Muller JM, Ziegler-Heitbrock HW, Baeuerle PA (1993) Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 187:233-256 (Pubitemid 23150770)
29. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64:987-991 (Pubitemid 40388448)
30. Preiningerova J (2009) Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 18:985-989
31. Raasch J, Zeller N, van Loo G, Merkler D, Mildner A, Erny D, Knobeloch KP, Bethea JR, Waisman A, Knust M, Del Turco D, Deller T, Blank T, Priller J, Bruck W, Pasparakis M, Prinz M (2011) IkappaB kinase 2 determines oligodendrocyte loss by noncell-autonomous activation of NF-kappaB in the central nervous system. Brain 134:1184-1198
32. Runstrom A, Leanderson T, Ohlsson L, Axelsson B (2006) Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFNbeta k.o. and wild type mice. J Neuroimmunol 173:69-78
33. Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil SS (2012) Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 7:e33797
34. Selmaj K, Raine CS, Cannella B, Brosnan CF (1991) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-954
35. Sennbro CJ, Olin M, Edman K, Hansson G, Gunnarsson PO, Svensson LD (2006) Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling. Rapid Commun Mass Spectrom 20:3313-3318 (Pubitemid 44763927)
36. Skihar V, Silva C, Chojnacki A, Doring A, Stallcup WB, Weiss S, Yong VW (2009) Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci USA 106:17992-17997
37. Smith KJ, Kapoor R, Felts PA (1999) Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9:69-92 (Pubitemid 29056521)
38. Steinman L, Zamvil SS (2005) Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 26:565-571 (Pubitemid 41726443)
39. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y (2006) Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 112:195-204
40. Thone J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G, Wiese S, Linker RA, Gold R (2012) Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180:267-274
41. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. New Engl J Med 338:278-285 (Pubitemid 28065253)
42. Trebst C, Heine S, Lienenklaus S, Lindner M, Baumgartner W, Weiss S, Stangel M (2007) Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination. Acta Neuropathol 114:587-596 (Pubitemid 350142747)
43. van Rossum D, Hilbert S, Strassenburg S, Hanisch UK, Bruck W (2008) Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype. Glia 56:271-283
44. Villarroya H, Violleau K, Ben Younes-Chennoufi A, Baumann N (1996) Myelin-induced experimental allergic encephalomyelitis in Lewis rats: tumor necrosis factor alpha levels in serum and cerebrospinal fluid immunohistochemical expression in glial cells and macrophages of optic nerve and spinal cord. J Neuroimmunol 64:55-61
45. Watkins TA, Emery B, Mulinyawe S, Barres BA (2008) Distinct stages of myelination regulated by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system. Neuron 60:555-569
46. Wegner C, Stadelmann C, Pfortner R, Raymond E, Feigelson S, Alon R, Timan B, Hayardeny L, Bruck W (2010) Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 227:133-143
47. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 156:3-9 (Pubitemid 39310510)
48. Yuen T, Zhang W, Ebersole BJ, Sealfon SC (2002) Monitoring G-protein-coupled receptor signalingwithDNAmicroarrays and realtime polymerase chain reaction. Methods Enzymol 345:556-569
49. Zaheer A, Yorek MA, Lim R (2001) Effects of glia maturation factor overexpression in primary astrocytes on MAP kinase activation, transcription factor activation, and neurotrophin secretion. Neurochem Res 26:1293-1299 (Pubitemid 34184028)